This Is MS Multiple Sclerosis Knowledge & Support Community

Posted: **Mon Sep 19, 2011 11:58 pm**

Immunological and clinical consequences of treating a patient with natalizumab

Abstract

Background: Long-term therapy with natalizumab increases the risk of progressive multifocal leukoencephalopathy (PML).

Objectives: We present a patient study through therapy, the diagnosis of PML (after 29 infusions), plasma exchange (PE) and development of immune reconstitution inflammatory syndrome (IRIS).... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768

Posted: **Tue Sep 20, 2011 1:54 am**

Additional info from the abstract...

With no clinical, routine laboratory or cerebrospinal fluid (CSF) changes, MRI 2 months after PE demonstrated progressive lesion development. Brain histopathology confirmed the presence of infiltrates indicative of IRIS without clinical signs, immunologically accompanied by CCR7/CCR5 recovery of peripheral monocytes.

Conclusion: Natalizumab-associated immunological changes accompanying PML were reversible after PE; IRIS can occur very late, remain asymptomatic and be elusive to CSF analysis.

NHE

This Is MS Multiple Sclerosis Knowledge & Support Community

Immunological and clinical consequences of Tysabri

Immunological and clinical consequences of Tysabri

Re: Immunological and clinical consequences of Tysabri